Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes
- 1 September 2019
- journal article
- research article
- Published by Elsevier in Journal of Substance Abuse Treatment
- Vol. 104, 34-41
Abstract
No abstract availableKeywords
Funding Information
- National Institute on Drug Abuse (R01 DA029910, K24 DA017072, R01 DA033679)
- Fogarty International Center (D43TW000233)
- National Institute of Allergy and Infectious Diseases (R25 TW009338)
This publication has 56 references indexed in Scilit:
- At the crossroads: HIV prevention and treatment for people who inject drugs in UkraineAddiction, 2013
- Mitigating the risk of HIV infection with opioid substitution treatmentBulletin of the World Health Organization, 2013
- Validating a Shortened Depression Scale (10 Item CES-D) among HIV-Positive People in British Columbia, CanadaPLOS ONE, 2012
- Retention on Buprenorphine Is Associated with High Levels of Maximal Viral Suppression among HIV-Infected Opioid Dependent Released PrisonersPLOS ONE, 2012
- Naltrexone extended-release injection: an option for the management of opioid abuseSubstance Abuse and Rehabilitation, 2011
- Decision aids for people facing health treatment or screening decisions2011
- HIV Treatment Outcomes Among HIV-Infected, Opioid-Dependent Patients Receiving Buprenorphine/Naloxone Treatment within HIV Clinical Care Settings: Results From a Multisite StudyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- The Soviet doctor and the treatment of drug addiction: "A difficult and most ungracious task"Harm Reduction Journal, 2011
- Assessing the Quality of Decision Support Technologies Using the International Patient Decision Aid Standards instrument (IPDASi)PLOS ONE, 2009
- HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine—programme description and policy implicationsInternational Journal of Drug Policy, 2007